Table of Contents
Development of Drugs for Resistant Pathogens
Development of Drugs for Resistant Pathogens
Development of Drugs for Resistant Pathogens Characteristics to Justify Development
Development of Drugs for Resistant Pathogens Preclinical IND Criteria
Development of Drugs for Resistant Pathogens Problems With IV Only Drugs
Antimicrobial Resistance in Nosocomial Pathogens
Drug Resistance in the USA Cubist SECURE surveillance study, 50 Centers
Penicillinase-Producing Staphylococcus aureus
Nosocomial Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Methicillin-Resistant Staphylococcus aureus: SFGH
MRSA in Bay Area Communities
Reports of Community-Acquired MRSA
Resistant Pathogens Nosocomial Enterococci Infections Resistant to Vancomycin*
Antibacterial Drugs in Development
Development of New Chemical Entity
Development of Drugs for Resistant Pathogens
Action Item 82
Action Item 82
Action Item 80
Development of Drugs for Resistant Pathogens Drug Categories
Development of Drugs for Resistant Pathogens Drug Categories
Vancomycin Use in the US
Development of Drugs for Resistant Pathogens Opinion
Development of Drugs for Resistant Pathogens Opinion
Development of Drugs for Resistant Pathogens Cubist Path with IV Only Narrow Spectrum Drug
Development of Drugs for Resistant Pathogens What is the answer? – Frank Tally
Development of Drugs for Resistant Pathogens What is the answer? – Frank Tally
Development of Drugs for Resistant Pathogens What is the answer? – Frank Tally
|